OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards.
The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma and biotechnology companies. The awards use feedback exclusively from experienced industry leaders to evaluate CDMOs across key performance metrics. OXB's recognition reflects the Company's excellence in quality, innovation and service capabilities across its integrated global network of facilities, and highlights its growing position as a world-leading cell and gene therapy CDMO.
Dr. Sebastien Ribault, Chief Business Officer of OXB, said: "We are honoured to receive this recognition which validates our successful transformation into a pure-play cell and gene therapy CDMO. This award reflects both our 30-year heritage of innovation in viral vectors and the success of our 'One OXB' multi-vector, multi-site strategy across the UK, US and France. Most importantly, it acknowledges our team's commitment to quality and collaboration as we work alongside our clients to enable the delivery of life-changing therapies to patients worldwide."
This industry recognition coincides with a period of strong commercial momentum for OXB, with growing demand for its CDMO services across all key viral vector types and an expanding global client portfolio spanning multiple development stages from early clinical work through to commercialisation.
-Ends-
Enquiries:
OXB:
Sebastien Ribault, Chief Business Officer – T: +44 (0) 1865 783 000 / E: partnering@oxb.com
ICR Healthcare:T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Here's how much passive income a 21-year-old investing £60 a week could earn by 35!
One way some financially savvy people earn passive income is by regularly investing money into shares that pay dividends. I like that approach for a number of reasons. It is simple, allows someone to benefit from the hard work of successful companies, and can be adapted to each person's own financial circumstances. For example, imagine someone starts doing this aged 21, with £60 a week. Here is what they could be earning by 35. One approach would be to invest the money and receive any dividends along the way. Personally, I prefer a second approach, which involves reinvesting those dividends (known as compounding). Compounding at an annual rate of 7%, the portfolio ought to be worth over £72,600 by 35. At a 7% dividend yield, that could generate around £5,083 of passive income each year. I think 7% is a realistic target in the current market while sticking to carefully selected blue-chip shares. Dividends are never guaranteed. Compound annual returns can be affected by share price moves too – prices can down as well as up. So, careful selection of a diversified portfolio of quality shares is the order of the day. Before getting onto that, though, it is necessary to have somewhere to put that £10 each week. So a useful, practical first move to put this passive income plan into action would be to set up a share-dealing account, Stocks and Shares ISA, or trading app. Another important step – and one I think it is well worth taking time over if necessary – is looking for income shares to buy. What makes for a good income share? Different people have their own ideas, but I think it is helpful if a company has a proven ability to generate more spare cash than it needs. So, it can be helpful for a company to have a mature business that does not require very high ongoing investment. An example of such a company I think investors should consider is British American Tobacco (LSE: BATS). The Lucky Strike maker has long been a massive cash generator. Cigarettes are cheap to make but can be sold expensively – and it sells millions every day, around the world. The dividend yield stands at 6.6%. British American is one of the few FTSE 100 companies to have raised its dividend per share annually for decades. No dividend is ever guaranteed, though. Cigarette use is declining in many markets and that poses a risk to profits for British American. Whether it can keep its cash cow generating lots of spare cash in coming decades, while building its non-cigarette business, will be critical when it comes to the firm's long-term performance. That will matter for many investors' passive income plans. For now, at least, British American's brand portfolio, multinational operations, and large customer base mean that it continues to generate sizeable free cash flows. The post Here's how much passive income a 21-year-old investing £60 a week could earn by 35! appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool C Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended British American Tobacco P.l.c. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
£10,000 invested in Greggs shares a year ago is now worth…
Over the long term, Greggs (LSE: GRG) has been a decent stock market performer. In the past five years, Greggs shares have moved up 18%. Over 10 years, the share price is up 69%. More recently, though, things have looked far less rosy – something I see as an opportunity. Take the past year as an example. During that time, Greggs shares have lost 31% of their value. So, someone who invested £10,000 in the bakery chain a year ago would now be nursing a paper loss of around £3,100. Ouch. Now, there would have been dividends along the way too. The current yield is 3.6%, although the higher share price a year ago means that someone who invested then would be earning around 2.4%. That would still have added up to approximately £240 over the course of year. That does not much help the overall performance, though, given that £3,100 paper loss. What has gone wrong? City worries about weak growth combined with higher costs due to increased staff wage bills have hurt investors' confidence in the stock. Those fears have some grounding in reality, I reckon. They are risks. But I think the worry has been overdone. Last month, the company announced that sales grew in the first 20 weeks of the year. Not only did total sales grow, but even stripping out new shop openings and just looking at the like-for-like sales, there was growth of 2.9%. That sounds modest but does not indicate a company in poor health to me. The sausage roll maker has not changed its expectation for cost inflation and kept its full-year outlook the same as before. In other words, things sound like they are ticking over pretty much fine. Combined with ambitious shop opening plans, that could mean that Greggs has significant medium- and long-term growth opportunities ahead of it. It has a proven business model, strong brand, and an ability to create consumer buzz about what are essentially mundane products. That gives it pricing power. However, while I am upbeat about the outlook, the price fall in Greggs shares means that they now sell for 13 times earnings. That strikes me as cheap for a company like this one, that I think could be even more profitable in future than it is now. So I bought some Greggs shares several months ago. Last week, I then bought some more. I decided to act, not wait, as I do not expect the current price to be around in the long term. This is because I think the share looks undervalued. I am glad I did not invest a year ago, as I would now be nursing a large paper loss. At today's price, though, I reckon Greggs shares look like good value, so I was happy to invest. The post £10,000 invested in Greggs shares a year ago is now worth… appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool C Ruane has positions in Greggs Plc. The Motley Fool UK has recommended Greggs Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
an hour ago
- Yahoo
My Legal & General shares are being battered by rival Aviva! Time to consider switching?
Legal & General (LSE: LGEN) shares come with a trailing dividend yield of 8.36%, one of the highest on the FTSE 100. Usually, a yield that high would set alarm bells ringing. But I think it's sustainable. If I didn't, I wouldn't have bought the stock several times in 2023. What gives me confidence is its payout history. Over the past 15 years, Legal & General has increased its dividend every single year but one. The exception was 2020, during the Covid pandemic. I'll forgive that. The government was twisting arms at the time. Payments resumed the next year. Over 15 years, Legal & General's dividends have grown at a compound rate of 12.12% a year. That's impressive but one thing worries me. The growth rate has slipped to 6.62% over 10 years and just 3.98% over five. Closer inspection shows payouts have risen 5% in each of the past four years, but there's change coming. Between 2025 and 2027, the board only plans to increase them by 2% a year. I've defended that decision before. With such a generous yield, a lower growth rate didn't seem like a big deal. But put next to a broader slowdown in dividend growth, I'm no longer brushing it off quite so easily. This matters, because Legal & General shares have done badly. They're up just 3.4% over one year and less than 3% over five. In the same time, big FTSE 100 rival Aviva (LSE: AV.) grew 30% and 120%, respectively. That's a bruising comparison. Aviva's dividend growth is also a clear winner. Over the last five years, Aviva has grown its payout at a compound annual rate of 18.4%. It even paid a dividend in 2020, which now looks like a badge of honour. I'm clearly backing the slower horse, and Aviva's recent trading update has only widened the gap. On 15 May, the insurer heralded a 'great start' to 2025, with premiums rising by almost 10%. CEO Amanda Blanc sounded upbeat, saying the group had a strong balance sheet, clear strategy, and was hitting targets across growth areas. Aviva is now aiming for £2bn in operating profit by 2026, and cumulative cash remittances of more than £5.8bn by then. To be fair, Legal & General isn't asleep at the wheel. In March, it hailed 'strong' 2024 performance and unveiled a £500m share buyback. That's part of a wider £5bn capital return plan over three years, roughly 40% of its market value. I won't be switching horses. It always seems that the minute I change queues – at the airport, in the bank, wherever – the one I just left starts moving faster. That would surely happen if I hopped over to Aviva now. Also, I prefer the idea of buying laggards that could bounce back, rather than chasing winners after they've already flown. Now here's the clincher. Legal & General still pays me handsomely. I received £305 in dividends on Thursday and promptly reinvested the lot. Aviva offers a solid 5.75% yield. Investors might consider buying it for added growth potential. But for me, Legal & General's shareholder returns are too juicy. I've always had a sweet tooth. The post My Legal & General shares are being battered by rival Aviva! Time to consider switching? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Harvey Jones has positions in Legal & General Group Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
